Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

NCT04952402 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT04952402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04952402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 4
Overall status
Completed
Start date
July 9, 2021
Completion date
January 10, 2023
Enrollment
43 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, sars-cov2 infection